Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT

BINV-L
Internal request:
 	
Comment to consider including adjuvant olaparib as an option for select patients based on the OlympiA data presented at the American Society of Clinical Oncology (ASCO) meeting and published online in the New England Journal of Medicine on June 3, 2021.
 	
External request:
Submission from AstraZeneca to review the data for the inclusion of olaparib in the guidelines as a monotherapy option for the adjuvant treatment of patients with gBRCAm, HER2-negative early breast cancer at high risk of recurrence who have previously been treated with neoadjuvant or adjuvant chemotherapy. This request is based on the OlympiA study that was presented at the 2021 American Society of Clinical Oncology (ASCO) meeting and published online in the New England Journal of Medicine on June 3, 2021.
 	
*See Submission for specific changes requested.
	The panel consensus supported the inclusion of 1 year of adjuvant olaparib as an option to consider for the following indications:
	
	• Triple negative breast cancer (TNBC) and residual disease after preoperative therapy with taxane-, alkylator-, and anthracycline-based chemotherapy, if high risk and germline *BRCA1/2* mutations.
	  ○ This is a category 1 recommendation.
	
	• After adjuvant chemotherapy for those with germline *BRCA1/2* mutations and TNBC and ≥pT2 or ≥pN1 disease.
	  ○ This is a category 1 recommendation.
	
	• After adjuvant chemotherapy for those with germline *BRCA1/2* mutations and HR-positive, HER2-negative ≥4 positive lymph nodes.
	  ○ The panel consensus did not support a category 1 recommendation.
	
	• For those with germline *BRCA1/2* mutations and HR-positive, HER2-negative disease who received preoperative chemotherapy, if residual disease and a clinical stage, pathologic stage, estrogen receptor status, and tumor grade (CPS+EG) score ≥3.
	  ○ The panel consensus did not support a category 1 recommendation.
	
	Reference:
	Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021 Jun 3.
		
		23
		
		23
		
		22
		
		16
		
		22
		
		16
			
			0
			
			0
			
			1
			
			6
			
			1
			
			6
				
				1
				
				1
				
				1
				
				2
				
				1
				
				2
					
					8
					
					8
					
					8
					
					8
					
					8
					
					8